Artrya (ASX:AYA), a medical technology company commercialising its Salix AI-powered cloud platform for near real-time, point-of-care assessment and management of coronary artery disease, has announced that Tanner Health has commenced commercial use of the Salix Coronary Plaque module, generating the first fee-per-scan revenues for the company.
Tanner Health, a foundational US commercial customer, has expanded its use of the Salix Coronary Anatomy platform to include assessments using the Coronary Plaque module, integrating it seamlessly into their workflow.
Under the five-year commercial agreement signed in July, Tanner Health pays a monthly subscription fee for the Salix software and can now generate fee-per-scan revenue, supported by a US Category 1 CPT reimbursement rate of US$950 per assessment.
The module has been activated at Tanner Health’s primary hospital in Carrollton, Georgia, with plans to roll out across additional facilities in the near term.
John Konstantopoulos, Co-Founder and CEO of Artrya, said, "We are thrilled to commence clinical use of the Salix Coronary Plaque module at Tanner Health. Clinicians have welcomed the ease of activation, and our backend processes for billing and reimbursement are now fully established."
At the time of reporting, Artrya's share price was $4.00.